VTRS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Viatris Inc. is not a strong buy at the moment for a beginner investor with a long-term strategy. While there are positive catalysts such as the approval of Effexor® in Japan and analyst upgrades, the company's financial performance and technical indicators do not currently support a compelling entry point. The stock's pre-market price is slightly down, and hedge funds are selling, which indicates weak sentiment. For a long-term investor, it may be better to wait for stronger signals or improved financial metrics.
The MACD is below zero and negatively contracting, indicating bearish momentum. RSI is neutral at 35.549, and moving averages are converging, suggesting no strong trend. The stock is trading near its support level (S1: 13.148), with resistance at R1: 13.851. Overall, the technical indicators suggest a lack of clear direction.
Approval of Effexor® SR capsules in Japan for generalized anxiety disorder.
Analyst upgrades with increased price targets, reflecting optimism about the company's growth potential and cost-saving initiatives.
Hedge funds are selling, with a 247.32% increase in selling activity last quarter.
Financial performance shows declining net income (-34.15% YoY) and EPS (-30.23% YoY).
Pre-market price is down 0.22%, reflecting weak sentiment.
In Q4 2025, revenue increased by 4.97% YoY to $3.7 billion, but net income dropped by 34.15% YoY to -$340.1 million. EPS also declined by 30.23% YoY to -0.3. Gross margin improved slightly to 40.25%, up 1.80% YoY. Overall, the financials show mixed performance with growth in revenue but significant declines in profitability.
Analysts are generally optimistic about Viatris, with several upgrades and increased price targets. Barclays raised the target to $17, UBS to $20, and Argus to $15, citing growth potential, cost-saving initiatives, and an undervalued stock. However, some analysts maintain neutral ratings, indicating mixed sentiment.
